bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version   trieza therapeutics inc  pharmaceuticals cordo formdscom  sec filings of fundraisings and investments in hedge funds private equity firms startups and growing companies formdscom newest filter local trieza therapeutics inc industry pharmaceuticals see others in industry address  massachusetts avenue suite  cambridge ma phone  filings date filingtype reported sold incremental cash type exemptions link to raw filing  new   equity only b sec link  new   debt only b sec link directors and executives current and past name role david cordo executive luke evnin director daniel hicklin director executive bizapediacom  human validation companiespeopleproductsservicestrademarksaddressesphone book our system has detected a high number of page requests from your ip address please prove to us that you are a human to continue using our website please send me to the search subscription offer page after i successfully answer the word challenge bizapediapro searchperform unlimited searches via ouradvanced search form withbizapedia pro searchfind out more bizapediapro databuild custom data listsfor one or many stateswith bizapedia pro datafind out more  copyright   · bizapediacom · all rights reservedblogpro searchpro apicontact usterms of useprivacy policysitemapdesktop version abzena grants trieza therapeutics exclusive worldwide rights to an undisclosed antibody sequence for use with triezas viral vector technology to develop cancer treatments  deal profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  deal profile bciq overview      settings      support abzena grants trieza therapeutics exclusive worldwide rights to an undisclosed antibody sequence for use with triezas viral vector technology to develop cancer treatments abzena plc uk  smallcap biopharma  m on  market cap licensor this is a sample profile to view the full content of this profile and many others log in to bciq or sign up for a free trial today trieza therapeutics inc us  private biopharma licensee this is a sample profile to view the full content of this profile and many others log in to bciq or sign up for a free trial today active sample  announced   biocentury inc all rights reserved    terms  conditions  privacy policy home  therapeutics inc about partnering  investors careers contact meet your milestonesthe only fullservice dermatology cro that takes products from concept to approvaldoes your product have a reason to beour philosophy extends to both our clients and ourselves be the best we can bemeet with us you may wonder what makes us different from other cros over  of what we do is dermatology at therapeutics we nurture your ideas with thoughtfully integrated solutions we aim to be your preferred partner let us lead your dermatology product development program through the complex maze of nonclinical clinical and regulatory hurdles to an fda approvalget started strategy cro services technology assessment our top  press room   therapeutics inc legal  privacy   balboa ave suite  san diego ca    therapeutics inc  balboa ave suite  san diego ca   legal  privacy trieza therapeutics inc  company profile  biocentury publications archives bciq conferences version  free trial  subscribe sign in english   한국어 biocentury menu home  publications  publications home  biocentury bc innovations bc extra bc week in review current issues archives  archives home  basic search advanced search back issues bciq  bciq home  overview pipeline analyst financial analyst company analyst deal analyst conferences  conferences home  newsmakers bio€quity europe future leaders china healthcare summit other industry events elearning  elearning home  videos white papers follow us bciq  company profile bciq overview      settings      support biocentury print this       trieza therapeutics inc print preview export bookmark share with colleague general information  location cambridge mass  region new england  country us  business category cancer  year founded   website  lead product status preclinical  archive items are loading  financial information  financing summary  financing details  earnings summary  stocks annual chart  pipeline information  pipeline summary  pipeline details  deals information  deals summary  deals details about biocentury company overview management editorial  research contact contact us advertising  sponsorship career opportunities support forgot password customer service reprints faqs products  solutions products overview publications archives bciq conferences elearning rss feeds legal user agreement terms of use privacy policy your california privacy rights use of images follow us what is biocentury biocentury employs a fully integrated multimedia platform — including publications video online data solutions and conferences — to provide its audience with authoritative and uptodate intelligence about corporate strategy partnering emerging technology clinical data public policy and the financial markets sign in free trial   biocentury inc all rights reserved    terms  conditions  privacy policy set email alert dummy telangana news updates  hyderabad live news updates  business news live  telangana news updates  latest breaking news hyderabadnational news live  latest news on telangana  telangana news updates andhra pradesh news live  andhra pradesh latest news  latest news on telangana  telangana news updates  international news live latest international news updates  legal news live latest legal news updates  editorial news live latest editorial news updates  sports news live updates latest editorial news updates  health news live updates latest health news updates  pharma news live updates latest pharma news updates  woman news live updates latest woman news updates entertainment news live updates latest entertainment news  educationandcareer news live updates latest educationandcareer news indianwhitepaper gallery live news gallery  breaking news gallery indianwhitepaper vedios  live news videos  breaking news videos business national andhra pradesh telangana international legal editorial sports health pharma woman entertainment education and career home  news  pharma abzena grants composite human antibody technology licence to trieza therapeutics dec   posted by admin cambridge uk abzena plc a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products has signed a licence agreement with trieza therapeutics inc trieza trieza is a startup biotechnology company specialising in the discovery and development of immunomodulatory oncolytic viruses based in cambridge ma usaabzena has granted trieza an exclusive worldwide royalty bearing sublicensable licence to an undisclosed antibody sequence which was created using the group’s composite human antibody technology for exploitation in conjunction with trieza’s viral vector technology to develop novel therapies in oncologyabzena could receive up to m in development and commercial milestone payments as well as royalties on the sale of licensed products containing the abzena sequence dr john burt abzena’s ceo commented “this new licence deal with trieza provides the opportunity for abzena to benefit from the commercialisation of one of the assets originally developed by the group to exemplify its proprietary antibody humanization and deimmunisation technology  our abzena inside portfolio already has eleven products in the clinic that have benefitted from this technology”dr dan hicklin trieza therapeutics’ ceo said “we are pleased to enter this relationship with abzena access to abzena’s technology will accelerate the development of trieza’s portfolio of immunotherapeutic oncolytic virus product candidates” a a a latest videos all videos photo gallery all photos popular news amid fear of more defections congress herds its gujarat mlas to bengaluru ahead of rajya sabha polls jul   defection a constitutional sin jul   stop shadi ke shaheed jul   the web counselling abruptly stopped for technical problem jul   opposition using dalits as pawns jawahar jul   ap businessmen reject odisha for andhra pradesh jul   scroll to top trieza therapeutics inc ceo and executives  bloomberg july    pm et company overview of trieza therapeutics inc snapshotpeople  overviewboard memberscommittees key executives for trieza therapeutics inc nameboard relationshipstitleagedaniel j hicklin phd relationshipspresident and director trieza therapeutics inc board members nameboard relationshipsprimary companyagedaniel j hicklin phd  relationshipstrieza therapeutics incluke b evnin phd  relationshipsblade therapeutics incview all board members trieza therapeutics inc executive committees committee namechairpersonboard relationshipsmembersthere is no committee data available data is at least as current as the most recent definitive proxy request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup ceo compensation in this industry  industry range industry executive changesthere is no executive change data availablesponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact trieza therapeutics inc please visit  company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close